Jason Zemansky
Stock Analyst at Bank of America Securities
(4.60)
# 888
Out of 4,377 analysts
439
Total ratings
50.4%
Success rate
15.1%
Average return
Main Sectors:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintained: Buy | $59 | $45.81 | +28.79% | 28 | Jun 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $9 → $10 | $2.75 | +263.64% | 17 | Jun 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $30 | $8.74 | +243.25% | 38 | Jun 3, 2026 | |
| KROS Keros Therapeutics | Reiterated: Hold | $20 | $10.30 | +94.17% | 16 | Jun 3, 2026 | |
| IKT Inhibikase Therapeutics | Reiterated: Buy | $6 | $1.63 | +268.10% | 4 | Jun 3, 2026 | |
| LYEL Lyell Immunopharma | Reiterated: Sell | $12 | $11.97 | +0.25% | 11 | Jun 3, 2026 | |
| ABOS Acumen Pharmaceuticals | Reiterated: Buy | $8 | $2.15 | +272.09% | 12 | Jun 3, 2026 | |
| EIKN Eikon Therapeutics | Reiterated: Buy | $34 → $32 | $8.96 | +257.14% | 3 | Jun 3, 2026 | |
| LGND Ligand Pharmaceuticals | Maintained: Buy | $266 | $237.00 | +12.24% | 7 | Jun 2, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $29 | $17.34 | +67.24% | 32 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $203 | $195.34 | +3.92% | 11 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $26.64 | +38.89% | 14 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $214 | $94.22 | +127.13% | 47 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $96 → $101 | $67.61 | +49.39% | 32 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $536 → $550 | $486.98 | +12.94% | 23 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $67 | $71.48 | -6.27% | 45 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 | $23.19 | +7.81% | 36 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $1.78 | $3.13 | -43.13% | 33 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.3923 | +1,684.35% | 19 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $56.77 | n/a | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $12 | $4.18 | n/a | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $1 | $4.44 | n/a | 3 | Dec 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.11 | n/a | 2 | Nov 17, 2023 |
Travere Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: $59
Current: $45.81
Upside: +28.79%
Rocket Pharmaceuticals
Jun 3, 2026
Reiterated: Buy
Price Target: $9 → $10
Current: $2.75
Upside: +263.64%
Kura Oncology
Jun 3, 2026
Reiterated: Buy
Price Target: $30
Current: $8.74
Upside: +243.25%
Keros Therapeutics
Jun 3, 2026
Reiterated: Hold
Price Target: $20
Current: $10.30
Upside: +94.17%
Inhibikase Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $6
Current: $1.63
Upside: +268.10%
Lyell Immunopharma
Jun 3, 2026
Reiterated: Sell
Price Target: $12
Current: $11.97
Upside: +0.25%
Acumen Pharmaceuticals
Jun 3, 2026
Reiterated: Buy
Price Target: $8
Current: $2.15
Upside: +272.09%
Eikon Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $34 → $32
Current: $8.96
Upside: +257.14%
Ligand Pharmaceuticals
Jun 2, 2026
Maintained: Buy
Price Target: $266
Current: $237.00
Upside: +12.24%
Syndax Pharmaceuticals
May 21, 2026
Maintained: Buy
Price Target: $29
Current: $17.34
Upside: +67.24%
May 14, 2026
Maintained: Hold
Price Target: $203
Current: $195.34
Upside: +3.92%
May 14, 2026
Maintained: Buy
Price Target: $37
Current: $26.64
Upside: +38.89%
May 13, 2026
Maintained: Buy
Price Target: $214
Current: $94.22
Upside: +127.13%
May 13, 2026
Reiterated: Buy
Price Target: $96 → $101
Current: $67.61
Upside: +49.39%
May 7, 2026
Reiterated: Hold
Price Target: $536 → $550
Current: $486.98
Upside: +12.94%
Apr 30, 2026
Maintained: Hold
Price Target: $67
Current: $71.48
Upside: -6.27%
Apr 21, 2026
Maintained: Hold
Price Target: $25
Current: $23.19
Upside: +7.81%
Mar 30, 2026
Maintained: Sell
Price Target: $1.78
Current: $3.13
Upside: -43.13%
Feb 17, 2026
Reiterated: Buy
Price Target: $7
Current: $0.3923
Upside: +1,684.35%
Oct 30, 2024
Maintained: Buy
Price Target: n/a
Current: $56.77
Upside: n/a
Mar 28, 2024
Reiterated: Sell
Price Target: $15 → $12
Current: $4.18
Upside: n/a
Dec 26, 2023
Maintained: Sell
Price Target: $1
Current: $4.44
Upside: n/a
Nov 17, 2023
Rated: Hold
Price Target: n/a
Current: $13.11
Upside: n/a